Consumer medicine information

Olmesartan HCT-MYL

Olmesartan medoxomil + Hydrochlorothiazide

BRAND INFORMATION

Brand name

Olmesartan HCT-MYL

Active ingredient

Olmesartan medoxomil + Hydrochlorothiazide

Schedule

S4

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Olmesartan HCT-MYL.

What is in this leaflet

This leaflet answers some common questions about OLMESARTAN HCT - MYL.

It does not contain all the available information.

It does not take the place of talking to your doctor or pharmacist.

All medicines have risks and benefits. Your doctor has weighed the risks of you taking OLMESARTAN HCT - MYL against the benefits he/she expects it will have for you.

If you have any concerns about taking this medicine, ask your doctor or pharmacist.

Keep this leaflet with your OLMESARTAN HCT - MYL Tablets. You may need to read it again.

What OLMESARTAN HCT - MYL is used for

OLMESARTAN HCT - MYL is used to treat high blood pressure which is sometimes called hypertension.

Everyone has blood pressure. This pressure helps push blood all around your body. Your blood pressure changes at different times of the day, depending on how busy or worried you are. You have hypertension (high blood pressure) when your blood pressure stays higher than is needed, even when you are calm and relaxed.

There are usually no symptoms of hypertension. The only way of knowing that you have hypertension is to have your blood pressure checked on a regular basis. If high blood pressure is not treated it can lead to serious health problems, including stroke, heart disease and kidney failure.

How OLMESARTAN HCT - MYL works

OLMESARTAN HCT - MYL belongs to a group of medicines known as angiotensin-II receptor antagonists. Angiotensin-II is a substance produced in the body which causes blood vessels to tighten. OLMESARTAN HCT - MYL blocks the action of angiotensin-II and therefore relaxes your blood vessels. This helps lower your blood pressure.

OLMESARTAN HCT - MYL also contains a diuretic which reduces the amount of fluid in the body. This also helps to lower blood pressure.

Your doctor may have prescribed OLMESARTAN HCT - MYL for another reason. Ask your doctor if you have any questions about why OLMESARTAN HCT - MYL has been prescribed for you.

OLMESARTAN HCT - MYL is not addictive.

This medicine is available only with a doctor's prescription.

Before you take OLMESARTAN HCT - MYL

When you must not take it

  • Do not take OLMESARTAN HCT - MYL if you have an allergy to olmesartan, sulfonamide derived medicines (e.g. thiazide diuretics), or any of the ingredients listed at the end of this leaflet
    Symptoms of an allergic reaction to OLMESARTAN HCT - MYL may include skin rash, itchiness, shortness of breath, swelling of the face, lips or tongue, muscle pain or tenderness or joint pain.
  • you have serious problems with your kidneys
  • you have serious problems with your liver
  • you have low potassium or sodium levels in the blood
  • you have high calcium or uric acid levels in the blood.
  • you have diabetes and are taking a medicine called aliskiren to reduce blood pressure.

Do not take OLMESARTAN HCT - MYL if you are pregnant or breastfeeding. OLMESARTAN HCT - MYL may enter your womb or it may pass into the breast milk and there is the possibility that your baby may be affected.

If pregnancy is discovered OLMESARTAN HCT - MYL should be discontinued as soon as possible.

Do not take OLMESARTAN HCT - MYL after the expiry date printed on the pack or if the packaging is torn or shows signs of tampering.

If you are not sure whether you should start taking OLMESARTAN HCT - MYL, talk to your doctor.

Before you start to take it

Tell your doctor if you have allergies to:

  • any other medicines
  • any other substances, such as foods, preservatives or dyes.

Tell your doctor if you have or have had any medical conditions, especially the following:

  • kidney problems
  • liver problems
  • heart problems
  • diabetes
  • excessive vomiting or diarrhoea recently
  • gout
  • Systemic Lupus Erythematosus (SLE)
  • high levels of potassium in your blood.
  • problems with your adrenal glands (small glands above the kidneys)

You must also tell your doctor if you:

  • are following a very low salt diet
  • you are or intend to become pregnant or plan to breastfeed.
  • you are taking potassium supplements, potassium-sparing agents, potassium-containing salt substitutes or other medicines that may increase serum potassium (e.g., trimethoprim-containing products)
  • you have skin cancer or if you develop a new skin lesion during treatment. Treatment with hydrochlorothiazide, particularly long-term use with high doses, may increase the risk of some types of skin and lip cancer (non-melanoma skin cancer). Discuss with your doctor how to protect your skin from sun exposure, and avoid artificial tanning.

If you have not told your doctor about any of the above, tell him/her before you start taking OLMESARTAN HCT - MYL.

Taking other medicines

Tell your doctor or pharmacist if you are taking any other medicines, including any that you buy without a prescription from your pharmacy, supermarket or health food shop.

Some medicines and OLMESARTAN HCT - MYL may interfere with each other. These include:

  • other medicines used to treat high blood pressure
  • other diuretics, also known as fluid or water tablets
  • non-steroidal anti-inflammatory drugs (NSAIDs) or COX-2 inhibitors, medicines used to relieve pain, swelling and other symptoms of inflammation, including arthritis
  • potassium supplements or potassium-containing salt substitutes
  • other medicines that may increase serum potassium (e.g., trimethoprim-containing products)
  • lithium or antidepressant medicines
  • insulin and tablets used to treat diabetes
  • antacids, medicines used to treat heartburn and indigestion
  • medicines which lower your immune system, such as corticosteroids and cytotoxic medicines used to treat cancer (including radiation therapy)
  • alcohol
  • laxatives, medicines used to treat constipation
  • medicines used to relieve pain
  • medicines used to treat epilepsy
  • antiarrhythmics which treat irregular heart beats
  • muscle relaxants
  • cholestyramine and colestipol, used to treat high cholesterol
  • any medicine that contains aliskiren
  • any medicines that contain colesevelam.

These medicines may be affected by OLMESARTAN HCT - MYL, or may affect how well it works. You may need different amounts of your medicine, or you may need to take different medicines.

Other medicines not listed above may also interfere with OLMESARTAN HCT - MYL. Your doctor and pharmacist have more information on medicines to be careful with or avoid while taking this medicine.

Use in children

The safety and effectiveness of OLMESARTAN HCT - MYL in children has not been established.

How to take OLMESARTAN HCT - MYL

Follow all directions given to you by your doctor or pharmacist carefully. They may differ from the information contained in this leaflet.

Your doctor or pharmacist will tell you which OLMESARTAN HCT - MYL tablet you will need to take each day. This depends on your condition and whether or not you are taking any other medicines.

If you do not understand the instructions on the box, ask your doctor or pharmacist for help.

How much to take

The dose of OLMESARTAN HCT - MYL is one tablet to be taken once a day.

How to take it

Swallow OLMESARTAN HCT - MYL whole with a full glass of water.

Do not chew the tablets.

When to take it

Take OLMESARTAN HCT - MYL at about the same time each day, with or without food. Taking your tablets at the same time each day will have the best effect.

It will also help you remember when to take the tablets. It does not matter whether you take it with or without food.

How long to take it

OLMESARTAN HCT - MYL helps control your condition, but does not cure it. Therefore you must take OLMESARTAN HCT - MYL every day. Continue taking your medicine for as long as your doctor tells you.

If you forget to take it

If it is almost time for your next dose, skip the dose you missed and take your next dose when you are meant to.

Otherwise, take it as soon as you remember and then go back to taking your medicine as you would normally.

Do not take a double dose to make up for the dose that you missed. This may increase the chance of you getting an unwanted side effect.

If you are not sure what to do, ask your doctor or pharmacist.

If you have trouble remembering to take your medicine, ask your pharmacist for some hints.

If you take too much (overdose)

Immediately telephone your doctor or the Australian Poisons Information Centre (telephone 13 11 26) or go to Accident and Emergency at the nearest hospital, if you think that you or anyone else may have taken too much OLMESARTAN HCT - MYL. Do this even if there are no signs of discomfort or poisoning.

Keep telephone numbers for these places handy.

If you take too much OLMESARTAN HCT - MYL, you may feel light-headed, dizzy or you may faint. You may also have a fast heart beat.

While you are using OLMESARTAN HCT - MYL

Things you must do

If you are about to be started on any new medicine, tell your doctor, dentist or pharmacist that you are taking OLMESARTAN HCT - MYL.

Make sure you drink enough water during exercise and hot weather when you are taking OLMESARTAN HCT - MYL, especially if you sweat a lot. If you do not drink enough water while taking OLMESARTAN HCT - MYL, you may feel faint, light-headed or sick. This is because your blood pressure is dropping suddenly. If you continue to feel unwell, tell your doctor.

If you have excess vomiting and/or diarrhoea, while taking OLMESARTAN HCT - MYL, tell your doctor. You may lose too much water and salt and your blood pressure may drop too much.

If you feel light-headed or dizzy after taking your first dose of OLMESARTAN HCT - MYL, or when your dose is increased, tell your doctor immediately.

If you plan to have surgery that needs a general anaesthetic, tell your doctor or dentist that you are taking OLMESARTAN HCT - MYL. Your blood pressure may drop suddenly.

If you become pregnant while taking OLMESARTAN HCT - MYL, tell your doctor immediately.

If you are about to have any blood tests, tell your doctor that you are taking OLMESARTAN HCT - MYL. OLMESARTAN HCT - MYL may interfere with the results of some tests.

Tell your doctor if photosensitivity reaction occurs during your treatment.

Tell your doctor immediately in case of acute onset of decreased visual acuity or ocular pain. These could be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or an increase of pressure in your eye and can happen within hours to weeks of taking OLMESARTAN HCT - MYL. This can lead to permanent vision loss, if not treated.

Tell your doctor immediately if you experience any fever, severe shortness of breath, breathing faster than normal, difficulty breathing, slightly blue fingertips and lips after taking OLMESARTAN HCT - MYL. Stop the medication and seek medical attention immediately.

Have your blood pressure checked when your doctor says, to make sure OLMESARTAN HCT - MYL is working.

Go to your doctor regularly for a check-up. Your doctor may occasionally do a blood test to check your potassium levels and see how your kidneys are working.

Things you must not do

Do not give OLMESARTAN HCT - MYL to anyone else, even if they have the same condition as you.

Do not take OLMESARTAN HCT - MYL to treat any other complaints unless your doctor or pharmacist tells you to.

Do not stop taking OLMESARTAN HCT - MYL, or lower the dosage, without checking with your doctor.

Things to be careful of

If you feel light-headed, dizzy or faint when getting out of bed or standing up, get up slowly. Standing up slowly, especially when you get up from bed or chairs, will help your body get used to the change in position and blood pressure. If this problem continues or gets worse, talk to your doctor.

Be careful driving or operating machinery until you know how OLMESARTAN HCT - MYL affects you. As with other medicines in this class, OLMESARTAN HCT - MYL may cause dizziness, light-headedness or tiredness in some people. Make sure you know how you react to OLMESARTAN HCT - MYL before you drive a car, operate machinery, or do anything else that could be dangerous if you are dizzy or light-headed. If this occurs do not drive. If you drink alcohol, dizziness or light-headedness may be worse.

Things that would be helpful for your blood pressure

Some self help measures suggested below may help your condition. Talk to your doctor or pharmacist about these measures and for more information.

  • Alcohol - your doctor may advise you to limit your alcohol intake.
  • Weight - your doctor may suggest losing some weight to help lower your blood pressure and help lessen the amount of work your heart has to do. Some people may need a dietician's help to lose weight.
  • Diet - eat a healthy diet which includes plenty of fresh vegetables, fruit, bread (preferably wholegrain), cereals and fish. Also eat less sugar and fat (especially saturated fat) which includes sausages, fatty meats, full cream dairy products, biscuits, cakes, pastries, chocolates, chips and coconut. Monounsaturated and polyunsaturated fats from olive oil, canola oil, avocado and nuts are beneficial in small quantities.
  • Salt - your doctor may advise you to watch the amount of salt in your diet. To reduce your salt intake you should avoid using salt in cooking or at the table and avoid cooked or processed foods containing high sodium (salt) levels.
  • Exercise - regular exercise, maintained over the long term, helps to reduce blood pressure and helps get the heart fitter. Regular exercise also improves your blood cholesterol levels, helps reduce your weight and stress levels, and improves your sleep, mood and ability to concentrate. However, it is important not to overdo it. Walking is good exercise, but try to find a route that is reasonably flat. Before starting any exercise, ask your doctor about the best kind of programme for you.
  • Smoking - your doctor may advise you to stop smoking or at least cut down. There are enormous benefits to be gained from giving up smoking. There are many professionals, organisations and strategies to help you quit. Ask your doctor or pharmacist for further information and advice.

Side effects

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are taking OLMESARTAN HCT - MYL.

OLMESARTAN HCT - MYL helps most people with high blood pressure, but it may have unwanted side effects in a few people. All medicines can have side effects. Sometimes they are serious, most of the time they are not. You may need medical treatment if you get some of the side effects.

If you are over 65 years of age you may have an increased chance of getting side effects.

Hydrochlorothiazide, a component of this medicine, increases sensitivity of the skin to the sun and may increase the risk of some types of skin and lip cancer (non-melanoma skin cancer).

Hydrochlorothiazide, a component of this medicine, may cause a decrease in vision or pain in your eyes due to high pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle-closure glaucoma).

Hydrochlorothiazide, a component of this medicine, may cause fever, severe shortness of breath, breathing faster than normal, difficulty breathing, slightly blue fingertips and lips. Ask your doctor or pharmacist to answer any questions you may have.

The following is a list of possible side effects. Do not be alarmed by this list. You may not experience any of them.

Tell your doctor or pharmacist if you notice any of the following and they worry you:

  • feeling light-headed, dizzy or faint
  • cough
  • headache
  • feeling sick (nausea) or vomiting
  • stomach pain
  • diarrhoea or constipation
  • an uncomfortable feeling in the stomach
  • unusual tiredness or weakness, fatigue
  • 'flu-like' symptoms
  • runny or blocked nose, or sneezing
  • bronchitis
  • sore throat and discomfort when swallowing (pharyngitis)
  • swelling of the hands, feet or ankles
  • back pain
  • urinary tract infection
  • jaundice
  • blurred vision
  • skin rashes or eczema
  • sleep disturbance
  • depression.

These are common side effects. They are generally mild.

Tell your doctor as soon as possible if you notice any of the following:

  • skin rash or itchiness
  • aching, tender or weak muscles not caused by exercise
  • painful joints
  • fast heart beat
  • shortness of breath or tightness in the chest
  • swelling of the hands, feet or ankles
  • yellowing of the whites of the eyes, dark urine and itching of the skin.
  • symptoms that may indicate high potassium levels in the blood, such as nausea, diarrhoea, muscle weakness, change in heart rhythm.

These may be serious side effects. You may need medical attention. Serious side effects are rare.

If any of the following happen, stop taking OLMESARTAN HCT - MYL and either tell your doctor immediately or go to Accident and Emergency at your nearest hospital:

  • swelling of the face, lips, mouth, tongue or throat which may cause difficulty in swallowing or breathing
  • chest pain.

These are very serious side effects. You may need urgent medical attention or hospitalisation. These side effects are very rare.

Other side effects not listed above may occur in some patients. Tell your doctor or pharmacist if you notice anything that is making you feel unwell.

After using OLMESARTAN HCT - MYL

Storage

Keep your tablets in the box until it is time to take them. If you take the tablets out of the box they will not keep well.

Keep your tablets in a cool dry place where the temperature stays below 25°C.

Do not store OLMESARTAN HCT - MYL or any other medicine in the bathroom or near a sink.

Do not leave it on a windowsill or in the car on hot days. Heat and dampness can destroy some medicines.

Keep it where children cannot reach it. A locked cupboard at least one-and-a-half metres above the ground is a good place to store medicines.

Disposal

If your doctor tells you to stop taking OLMESARTAN HCT - MYL or the tablets have passed their expiry date, ask your pharmacist what to do with any that are left over.

Product description

What it looks like

OLMESARTAN HCT - MYL tablets come in three strengths and each has a different appearance:

OLMESARTAN HCT - MYL 20/12.5mg is a round tablet, approximately 8.5mm in diameter, reddish yellow in colour with C22 debossed on one side.

OLMESARTAN HCT - MYL 40/12.5mg is an oval tablet, approximately 15mm x 7mm, reddish yellow in colour with C23 debossed on one side.

OLMESARTAN HCT - MYL 40/25mg is an oval tablet, approximately 15mm x 7mm in diameter, pinkish in colour with C25 debossed on one side.

The product is presented in blister packs of 10 or 30 film-coated tablets.

Ingredients

Active ingredients:

OLMESARTAN HCT - MYL 20/12.5 - 20mg olmesartan medoxomil and 12.5mg hydrochlorothiazide

OLMESARTAN HCT - MYL 40/12.5 - 40mg olmesartan medoxomil and 12.5mg hydrochlorothiazide

OLMESARTAN HCT - MYL 40/25 - 40mg olmesartan medoxomil and 25mg hydrochlorothiazide

Other ingredients:

  • microcrystalline cellulose
  • lactose monohydrate
  • hyprolose
  • magnesium stearate
  • and Opadry O2A22352 or Opadry O2A24576 that contain titanium dioxide, purified talc, hypromellose and iron oxides.

OLMESARTAN HCT - MYL does not contain sucrose, tartrazine or any other azo dyes.

Supplier

OLMESARTAN HCT - MYL is supplied in Australia by:

Organon Pharma Pty Ltd
Building A, 26 Talavera Road,
Macquarie Park NSW 2113

Australian Registration Numbers

OLMESARTAN HCT - MYL 20/12.5
AUST R 273576

OLMESARTAN HCT - MYL 40/12.5
AUST R 273577

OLMESARTAN HCT - MYL 40/25
AUST R 273578

This leaflet was prepared in August 2022.

Published by MIMS October 2022

BRAND INFORMATION

Brand name

Olmesartan HCT-MYL

Active ingredient

Olmesartan medoxomil + Hydrochlorothiazide

Schedule

S4

 

1 Name of Medicine

Olmesartan medoxomil and hydrochlorothiazide.

2 Qualitative and Quantitative Composition

Olmesartan HCT-MYL consists of olmesartan medoxomil and hydrochlorothiazide (HCTZ).
Olmesartan HCT-MYL 20/12.5 contains 20 mg of olmesartan medoxomil and 12.5 mg of hydrochlorothiazide.
Olmesartan HCT-MYL 40/12.5 contains 40 mg of olmesartan medoxomil and 12.5 mg of hydrochlorothiazide.
Olmesartan HCT-MYL 40/25 contains 40 mg of olmesartan medoxomil and 25 mg of hydrochlorothiazide.
Olmesartan medoxomil is a white to light yellowish-white powder or crystalline powder. It is practically insoluble in water and sparingly soluble in methanol.
HCTZ is a white, or almost white, crystalline powder. HCTZ is very slightly soluble in water, soluble in acetone, sparingly soluble in alcohol. It dissolves in dilute solutions of alkali hydroxides.
Excipients with known effect. Lactose (as monohydrate).
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Olmesartan HCT-MYL is available for oral use as film-coated tablets containing 20/12.5 mg, 40/12.5 mg, or 40/25 mg olmesartan medoxomil/HCTZ.
Olmesartan HCT-MYL (olmesartan medoxomil/hydrochlorothiazide) 20/12.5 mg is a round tablet, approximately 8.5 mm in diameter, reddish yellow in colour with C22 debossed on one side.
Olmesartan HCT-MYL (olmesartan medoxomil/hydrochlorothiazide) 40/12.5 mg is an oval tablet, approximately 15 mm x 7 mm, reddish yellow in colour with C23 debossed on one side.
Olmesartan HCT-MYL (olmesartan medoxomil/hydrochlorothiazide) 40/25 mg is an oval tablet, approximately 15 mm x 7 mm in diameter, pinkish in colour with C25 debossed on one side.

4 Clinical Particulars

4.9 Overdose

No specific information is available on the effects or treatment of Olmesartan HCT-MYL overdosage. The patient should be closely monitored, and the treatment should be symptomatic and supportive. Management depends upon the time since ingestion and the severity of the symptoms. Activated charcoal may be useful in the treatment of overdosage. Serum electrolytes and creatinine should be monitored frequently. If hypotension occurs, the patient should be placed in a supine position, with salt and volume replacements given quickly.
The most likely manifestations of olmesartan overdosage are expected to be hypotension and tachycardia; bradycardia might also occur. Overdosage with HCTZ is associated with electrolyte depletion (hypokalaemia, hypochloraemia) and dehydration resulting from excessive diuresis. The most common signs and symptoms of overdosage are nausea and somnolence. Hypokalaemia may result in muscle spasm and/or accentuate cardiac arrhythmias associated with the concomitant use of digitalis glycosides or certain anti-arrhythmic drugs.
No information is available regarding the dialysability of olmesartan or HCTZ.
For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5 Pharmacological Properties

5.3 Preclinical Safety Data

Genotoxicity. Olmesartan medoxomil. Both olmesartan medoxomil and olmesartan tested negative in the in vitro Syrian hamster embryo cell transformation assay and showed no evidence of genetic toxicity in the Ames (bacterial mutagenicity) test. However, both were shown to induce chromosomal aberrations in cultured cells in vitro (Chinese hamster lung) and tested positive for thymidine kinase mutations in the in vitro mouse lymphoma assay. Olmesartan medoxomil tested negative in vivo for mutations in the intestine and kidney of a mutagenic susceptible mouse (MutaMouse) and for clastogenicity in mouse bone marrow (micronucleus test) at oral doses of up to 2,000 mg/kg/day. Olmesartan not tested in this mouse model. On balance, the weight-of-evidence indicates that olmesartan medoxomil does not pose a genotoxic risk at clinically relevant doses.
HCTZ. HCTZ was negative in several different assays of gene mutation and chromosomal aberration. However, positive test results were obtained in the in vitro CHO sister chromatid exchange (clastogenicity) assay and the mouse lymphoma (mutagenicity) assay at HCTZ concentrations of 43-1,200 microgram/mL.
Olmesartan medoxomil and HCTZ. Olmesartan medoxomil/HCTZ in a ratio of 20:12.5 was negative in the bacterial reverse mutation test up to the maximum recommended plate concentration for the standard assays. As expected, positive clastogenicity responses were observed with either drug or the combination (40:12.5, 20:12.5, 10:12.5) in Chinese hamster lung cells but no synergistic clastogenicity was observed. However, the combination (20:12.5) was negative in the in vivo mouse micronucleus test at oral doses (1,935/1,209 mg/kg) that were likely to achieve high relative systemic exposure (> 33-700-fold based on AUC) to both components.
Carcinogenicity. The carcinogenic potential of olmesartan and HCTZ in combination has not been investigated.
Olmesartan medoxomil was not carcinogenic when administered by dietary administration to rats for up to 2 years. The highest dose tested (2,000 mg/kg/day) corresponded to a relative systemic exposure to olmesartan that was about 30 times that anticipated at the maximum recommended human dose (MRHD) of 40 mg/day (based on AUC). Two carcinogenicity studies conducted in mice, a 6-month gavage study in the p53 knockout mouse and a 6-month dietary administration study in the Hras2 transgenic mouse, at doses of up to 1,000 mg/kg/day (about 11 times anticipated clinical exposure to olmesartan at the MRHD, based on AUC in Hras2), revealed no evidence of a carcinogenic effect of olmesartan medoxomil.
Two-year feeding studies in mice and rats showed no evidence of carcinogenic potential for HCTZ in female mice at doses up to approximately 600 mg/kg/day, or in male and female rats at doses up to approximately 100 mg/kg/day. There was equivocal evidence for hepatocarcinogenicity in male mice treated with HCTZ at approximately 600 mg/kg/day.

6 Pharmaceutical Particulars

6.7 Physicochemical Properties

Olmesartan medoxomil is a prodrug, hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Olmesartan is a selective AT1 subtype angiotensin II receptor antagonist. HCTZ is a thiazide diuretic.
Olmesartan medoxomil is described chemically as 2,3-dihydroxy-2-butenyl 4-(1-hydroxy-1-methylethyl)- 2-propyl-1-[p-(o-1H-tetrazol-5-ylphenyl) benzyl] imidazole-5-carboxylate, cyclic 2,3-carbonate. Its empirical formula is C29H30N6O6 with a molecular weight of 558.59.
HCTZ is described chemically as 6-chloro-3,4-dihydro- 2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide. The empirical formula is C7H8ClN3O4S2 with a molecular weight of 297.7.
Chemical structure. The structural formula of olmesartan medoxomil is:
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSOLMMED.gif The structural formula of hydrochlorothiazide is:
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSHYDROC.gif CAS number. 144689-63-4 (olmesartan medoxomil); 58-93-5 (hydrochlorothiazide).

7 Medicine Schedule (Poisons Standard)

Prescription only medicine (S4).

Summary Table of Changes

https://stagingapi.mims.com/au/public/v2/images/fulltablegif/OLHMYLST.gif